Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This review concluded that interleukin-17 is involved in the development of female-pattern baldness, suggesting a potential inflammatory role in the condition’s underlying causes.

In this study, researchers observed an increased incidence of pattern hair loss and telogen effluvium among COVID-19 patients, potentially linked to psychological stress, systemic inflammation, and oxidative stress, with reduced anagenic expression of proteoglycans suggested as a mediating mechanism.

This review discusses the link between COVID-19 and diffuse hair loss, focusing on the potential of proteoglycan replacement therapy with Nourkrin® to treat pattern hair loss and telogen effluvium in affected patients, and reports no new clinical results.

This study found that treatment with a 1550 nm fractional erbium–glass laser increased hair density and thickness in women with female pattern hair loss, suggesting it may be an effective and safe option.

This study found that TGF-β1 expression in follicular tumors correlates with differentiation degree and suggests its potential role alongside p63 in differentiating between sebaceous and follicular tumors.

Male pattern hair loss could hint at androgens affecting COVID-19 severity.

This study observed that low-dose oral minoxidil and topical minoxidil 5% solution both improved hair density in women with female-pattern hair loss, but oral minoxidil may offer advantages in reducing hair shedding.

This study concluded that 12 sessions of fractionated thulium laser treatment improved hair density and thickness in patients with pattern hair loss, with further benefits from adding a growth factor solution post-treatment.

This study found that certain VDR gene polymorphisms are more prevalent in female pattern hair loss patients than in healthy controls, suggesting these polymorphisms may increase disease risk.

This prospective study found that 1,927-nm fractionated thulium laser treatment significantly increased hair and terminal hair counts in 11 men with pattern hair loss, although it did not change average hair thickness, suggesting it may be a promising therapy for this condition.

This study found that women experiencing hair loss after recovering from COVID-19 had significantly lower Vitamin D and ferritin levels and higher testosterone and triglyceride levels compared to those without hair loss, indicating a potential link between these factors and the condition.

This study reports distinctive clinical, trichoscopic, and histopathological features of fibrosing alopecia in a pattern distribution among Chinese patients, suggesting possible racial differences compared to previous studies primarily involving Caucasians.

This study found that oral minoxidil 1 mg daily was as effective and safe as topical minoxidil 5% solution for treating female pattern hair loss over 24 weeks, but more likely to cause excessive hair growth elsewhere.

This study found that male pattern baldness was associated with an increased risk of skin cancer at the head and neck, particularly affecting the scalp.

This study found that combining a thulium laser with intra-perifollicular PDRN injections significantly improved hair thickness but not hair counts compared to mesotherapy and PDRN in patients with pattern hair loss.

This study reported that Ell-Cranell® alpha 0.025% solution significantly increased hair counts and diameter in Korean women with female pattern hair loss over an 8-month period, showing both efficacy and safety.

This study reported that fibrosing alopecia in a pattern distribution can occur in patients of color, with clinical and histopathological features allowing for an accurate differential diagnosis.

This study suggests that the HDAC9 gene is a third susceptibility gene for male-pattern baldness, with significant associations found in both German and Australian samples.

This study found that the proteins GDNF, NTN, GFRα-1, GFRα-2, and c-Ret are differentially expressed during various stages of the human hair follicle cycle, with potential implications for hair biology.

This study found that women with female pattern baldness often had a higher ratio of 3 alpha,17 beta-androstanediol glucuronide to sex hormone-binding globulin and lower serum sex hormone-binding globulin, possibly indicating minimal androgen excess.

In this study, Korean women with female pattern hair loss who used a combination of topical 0.025% 17α-estradiol and 3% minoxidil saw significant increases in total hair count and hair caliber over six months.

This study reported that among postmenopausal women with female pattern hair loss, treatment with topical finasteride 0.5% and minoxidil 2% was more effective at improving hair condition than treatment with topical 17α-estradiol 0.05% and minoxidil 2%, particularly notable at 12-18 months of follow-up.

Higher levels of MiR-92a-1-5p and miR-328-3p found in female hair loss patients.

Low androgen levels can still cause female pattern hair loss.

In this case report, hair graying improved in a patient with male pattern hair loss after combined treatment with thulium laser energy and polydeoxyribonucleotide injections, suggesting potential therapeutic benefits.

This study observed that the COVID-19 pandemic altered the pattern of dermatoses among Iraqi females, with significant increases in hair loss and decreases in viral skin infections.

This study observed that during the COVID-19 pandemic, Iraqi females experienced significantly increased hair loss, while contagious viral infections decreased in a dermatology clinic setting.

This study found that oral spironolactone is generally well tolerated and may be effective for treating female-pattern hair loss, with improvements in hair regrowth stability as measured by Sinclair scores.

This study observed that male pattern hair loss patients are getting diagnosed earlier and presenting with milder forms, possibly due to early puberty, and noted frequent familial predisposition and comorbidities like seborrheic dermatitis.

In this study, both 5% and 10% topical minoxidil showed similar overall efficacy in treating male-pattern hair loss, though the 10% concentration resulted in greater improvement in frontal hair count but also more side effects.